• Lead Drug FGL Found To Prevent Impaired Cognition
• R&D Update, Publication & Conference Presentation
• CHDI selects ENKAM’s compounds for preclinical tes
• Presentation at BIO-Europe
• Attendance at Conferences
• Participation at Conference
• The ENKAM approach shows potential in treatment of
• Discovery of Novel Compound Classes
• Positive Preclinical Data - Traumatic Brain Injury
• Appointment of Executive Chairman
• New Promising Treatment of Alzheimer’s Disease
• EU 6FP Grants EUR9.7 million to European Research
• Glossary

Discovery of Novel Compound Classes 

      - presented at Key Conference

____________________________________________________________________

Copenhagen, Denmark June 10th, 2006 - ENKAM Pharmaceuticals A/S, the Copenhagen-based biotechnology company focused on cancer and neurodegenerative diseases, announces today that it will present new preclinical data at the 5th Forum of European Neuroscience (FENS) to be held 8-12 July, 2006 in Vienna.

At the conference ENKAM will present 6 posters on three novel classes of drug-candidates with a great potential to treat and prevent neurodegenerative disorders and cancer.

In the first novel class of compounds, positive preclinical data has been generated from NCAM[1]agonists Plannexin and Dennexin which are two new peptide families that have been named and discovered by Enkam. In a traumatic brain injury in vivo model, when delivered via sub-cutaneous injection, Plannexin was found to reduce oxidative stress, neurodegeneration and apoptosis (cell death) and Dennexin was found to inhibit the inflammatory response to brain trauma by reducing the number of macrophages and also the degree of inflammation. Both peptides were also tested in vitro and demonstrated neuroprotective properties.

The second novel compound class discovered by Enkam, which are FGF[2]receptor agonists, have been named Dyofins and Dekafins. Dyofins, peptides derived from various fibroblast growth factors (FGFs), were shown to activate the FGF-receptor, stimulate neurite outgrowth and have potential to reduce neurodegeneration in vivo.

Dekafins, also derived from FGFs, were all shown to bind to and activate the FGF-receptor. Selected groups of the Dekafins are a promising new class of tyrosin kinase modulaters with exiting potential within neurodegeneration and cancer.

The third novel compound class, Encamins, constituting a group of new FGF-receptor modulators, display neurite outgrowth-stimulating, neuroprotective and cognition-enhancing properties. One of these encamins, Encamin C, has a great potential to inhibit tumor cell growth in vitro and in vivo demonstrating a novel approach in development of anti-cancer treatments.

Commenting on this announcement, Morten Albrechtsen MD, Chief Executive and a founder of ENKAM Pharmaceuticals, said:“We are pleased to be presenting this data at this key conference. The in-vivo data that we are presenting for these novel targets is robust and these new peptide discoveries further strengthen our portfolio.”